RxDoctor Payments DataLook up a doctor →

David Butters, DO

Family Medicine · Layton, UTNPI 1932272598

Payments from drug & device makers

$189,239in general payments, 2019–2025

Across 950 payments — averaging $199.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$103K
  • Axsome Therapeutics, Inc.$22K
  • AstraZeneca$16K
  • Idorsia Pharmaceuticals US Inc$13K
  • Sunovion Pharmaceuticals Inc.$13K
  • Otsuka America Pharmaceutical, Inc.$12K
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)311$103,464
Axsome Therapeutics, Inc.27$21,913
AstraZeneca63$16,065
Idorsia Pharmaceuticals US Inc21$13,331
Sunovion Pharmaceuticals Inc.49$13,126
Otsuka America Pharmaceutical, Inc.36$11,901
Takeda Pharmaceuticals U.S.A., Inc.28$1,491
Biohaven Pharmaceuticals, Inc.7$1,282
Amarin Pharma, Inc.49$571
Lilly USA, LLC40$510
Boehringer Ingelheim24$466
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$447
Astellas Pharma US Inc22$427
Pfizer17$400
Novo Nordisk19$328
E.r. Squibb & Sons, L.L.C.15$313
Amgen17$269
Johnson & Johnson19$264
GSK17$246
Eisai Inc.18$222
Teva Pharmaceuticals USA, Inc.16$211
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$211
Abbott17$198
Sanofi-aventis U.S. LLC14$168
Biohaven Pharmaceutical Holding Company Ltd.5$131
Lucid Diagnostics Inc.3$111
Avanir Pharmaceuticals, Inc.6$96
Alkermes, Inc.6$96
Neurelis, Inc.6$89
Jazz Pharmaceuticals Inc.2$76
Otsuka Pharmaceutical Development & Commercialization, Inc.1$67
Sumitomo Pharma America, Inc.5$67
Merck4$61
Optinose US, Inc.3$55
Nestle Healthcare Nutrition Inc.3$54
Sanofi Pasteur Inc.3$50
Seqirus USA Inc3$39
Shire North American Group Inc3$35
Organon3$31
Lundbeck LLC2$29
Novartis2$27
Neurocrine Biosciences, Inc.1$23
Supernus Pharmaceuticals, Inc.1$19
Xeris Pharmaceuticals, Inc.1$19
Genentech USA, Inc.1$19
Kowa Pharmaceuticals America, Inc.1$18
Biogen1$18
Grifols USA, LLC1$18
Bolton Medical Inc1$17
Assertio Therapeutics, Inc.1$16
Amneal Pharmaceuticals LLC1$16
Tandem Diabetes Care, Inc.1$15
Currax Pharmaceuticals LLC1$14
Exact Sciences1$13
Bausch Health US, LLC1$13
Cranial Technologies, Inc1$12
Dexcom, Inc.1$12
Nalpropion Pharmaceuticals LLC1$12
Medtronic1$12
Ironwood Pharmaceuticals, Inc1$12

How this compares

$189,239 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$44,047
Medicare patients
97
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →